Which has higher valuation & earnings, LNTH or PEN?

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.56B 4.19 $233.56M $4.14 24.15 Penumbra $1.40B 9.12 $177.69M $4.07 79.89

Is LNTH or PEN more profitable?

Lantheus has a net margin of 17.69% compared to Penumbra's net margin of 10.67%. Lantheus' return on equity of 28.10% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% Penumbra 10.67% 10.50% 8.17%

Does the media favor LNTH or PEN?

In the previous week, Lantheus had 3 more articles in the media than Penumbra. MarketBeat recorded 11 mentions for Lantheus and 8 mentions for Penumbra. Penumbra's average media sentiment score of 1.51 beat Lantheus' score of 1.26 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation & earnings, PEN or ITGR?

Penumbra has higher earnings, but lower revenue than Integer. Integer is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 9.12 $177.69M $4.07 79.89 Integer $1.84B 2.31 $102.81M $3.66 34.21

Is PEN or ITGR more profitable?

Penumbra has a net margin of 10.67% compared to Integer's net margin of 6.97%. Integer's return on equity of 12.79% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% Integer 6.97% 12.79% 6.48%

Does the media refer more to PEN or ITGR?

In the previous week, Penumbra and Penumbra both had 8 articles in the media. Penumbra's average media sentiment score of 1.51 beat Integer's score of 1.42 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Integer 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PEN or BDX?

In the previous week, Becton, Dickinson and Company had 26 more articles in the media than Penumbra. MarketBeat recorded 34 mentions for Becton, Dickinson and Company and 8 mentions for Penumbra. Penumbra's average media sentiment score of 1.51 beat Becton, Dickinson and Company's score of 1.20 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Becton, Dickinson and Company 25 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, PEN or IDXX?

IDEXX Laboratories has higher revenue and earnings than Penumbra. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 9.12 $177.69M $4.07 79.89 IDEXX Laboratories $4.30B 10.19 $1.06B $14.22 39.17

Does the media refer more to PEN or IDXX?

In the previous week, IDEXX Laboratories had 1 more articles in the media than Penumbra. MarketBeat recorded 9 mentions for IDEXX Laboratories and 8 mentions for Penumbra. Penumbra's average media sentiment score of 1.51 beat IDEXX Laboratories' score of 0.98 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive IDEXX Laboratories 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, PEN or DXCM?

DexCom has higher revenue and earnings than Penumbra. DexCom is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 9.12 $177.69M $4.07 79.89 DexCom $4.66B 7.47 $836.30M $2.53 36.50

Is PEN or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Penumbra's net margin of 10.67%. DexCom's return on equity of 35.94% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% DexCom 20.12% 35.94% 14.75%

Does the media prefer PEN or DXCM?

In the previous week, DexCom had 15 more articles in the media than Penumbra. MarketBeat recorded 23 mentions for DexCom and 8 mentions for Penumbra. DexCom's average media sentiment score of 1.65 beat Penumbra's score of 1.51 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DexCom 22 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Penumbra (PEN) Competitors

$325.14 +1.38 (+0.43%)

As of 08/21/2026 03:58 PM Eastern

Compare

PEN vs. LNTH, ITGR, BDX, IDXX, and DXCM

Should you buy Penumbra stock or one of its competitors? Penumbra's main competitors and comparable companies include Lantheus (LNTH), Integer (ITGR), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), and DexCom (DXCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Penumbra compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Penumbra (NYSE:PEN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

In the previous week, Lantheus had 3 more articles in the media than Penumbra. MarketBeat recorded 11 mentions for Lantheus and 8 mentions for Penumbra. Penumbra's average media sentiment score of 1.51 beat Lantheus' score of 1.26 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Lantheus currently has a consensus price target of $108.11, suggesting a potential upside of 8.14%. Penumbra has a consensus price target of $367.07, suggesting a potential upside of 12.90%. Given Penumbra's higher probable upside, analysts clearly believe Penumbra is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Penumbra	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12

Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.56B	4.19	$233.56M	$4.14	24.15
Penumbra	$1.40B	9.12	$177.69M	$4.07	79.89

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 2.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lantheus has a net margin of 17.69% compared to Penumbra's net margin of 10.67%. Lantheus' return on equity of 28.10% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Penumbra	10.67%	10.50%	8.17%

Summary

Lantheus beats Penumbra on 10 of the 16 factors compared between the two stocks.

How does Penumbra compare to Integer?

Penumbra (NYSE:PEN) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Penumbra has a net margin of 10.67% compared to Integer's net margin of 6.97%. Integer's return on equity of 12.79% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
Integer	6.97%	12.79%	6.48%

Penumbra has higher earnings, but lower revenue than Integer. Integer is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.12	$177.69M	$4.07	79.89
Integer	$1.84B	2.31	$102.81M	$3.66	34.21

In the previous week, Penumbra and Penumbra both had 8 articles in the media. Penumbra's average media sentiment score of 1.51 beat Integer's score of 1.42 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Integer	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Penumbra has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Integer has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Penumbra presently has a consensus price target of $367.07, indicating a potential upside of 12.90%. Integer has a consensus price target of $109.86, indicating a potential downside of 12.27%. Given Penumbra's stronger consensus rating and higher probable upside, equities research analysts clearly believe Penumbra is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Summary

Penumbra beats Integer on 12 of the 15 factors compared between the two stocks.

How does Penumbra compare to Becton, Dickinson and Company?

Penumbra (NYSE:PEN) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Penumbra has a net margin of 10.67% compared to Becton, Dickinson and Company's net margin of 4.52%. Becton, Dickinson and Company's return on equity of 14.79% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
Becton, Dickinson and Company	4.52%	14.79%	6.93%

Penumbra currently has a consensus price target of $367.07, suggesting a potential upside of 12.90%. Becton, Dickinson and Company has a consensus price target of $185.67, suggesting a potential downside of 3.27%. Given Penumbra's higher probable upside, research analysts clearly believe Penumbra is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

In the previous week, Becton, Dickinson and Company had 26 more articles in the media than Penumbra. MarketBeat recorded 34 mentions for Becton, Dickinson and Company and 8 mentions for Penumbra. Penumbra's average media sentiment score of 1.51 beat Becton, Dickinson and Company's score of 1.20 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Becton, Dickinson and Company	25 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Penumbra shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Penumbra has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Becton, Dickinson and Company has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Becton, Dickinson and Company has higher revenue and earnings than Penumbra. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.12	$177.69M	$4.07	79.89
Becton, Dickinson and Company	$21.84B	2.42	$1.68B	$3.32	57.82

Summary

Penumbra beats Becton, Dickinson and Company on 10 of the 16 factors compared between the two stocks.

How does Penumbra compare to IDEXX Laboratories?

Penumbra (NYSE:PEN) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

IDEXX Laboratories has a net margin of 25.03% compared to Penumbra's net margin of 10.67%. IDEXX Laboratories' return on equity of 71.96% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
IDEXX Laboratories	25.03%	71.96%	33.60%

In the previous week, IDEXX Laboratories had 1 more articles in the media than Penumbra. MarketBeat recorded 9 mentions for IDEXX Laboratories and 8 mentions for Penumbra. Penumbra's average media sentiment score of 1.51 beat IDEXX Laboratories' score of 0.98 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
IDEXX Laboratories	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Penumbra shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 2.9% of Penumbra shares are held by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

IDEXX Laboratories has higher revenue and earnings than Penumbra. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.12	$177.69M	$4.07	79.89
IDEXX Laboratories	$4.30B	10.19	$1.06B	$14.22	39.17

Penumbra currently has a consensus target price of $367.07, indicating a potential upside of 12.90%. IDEXX Laboratories has a consensus target price of $747.00, indicating a potential upside of 34.13%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

Penumbra has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

Summary

IDEXX Laboratories beats Penumbra on 12 of the 16 factors compared between the two stocks.

How does Penumbra compare to DexCom?

Penumbra (NYSE:PEN) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

DexCom has higher revenue and earnings than Penumbra. DexCom is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.12	$177.69M	$4.07	79.89
DexCom	$4.66B	7.47	$836.30M	$2.53	36.50

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

DexCom has a net margin of 20.12% compared to Penumbra's net margin of 10.67%. DexCom's return on equity of 35.94% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
DexCom	20.12%	35.94%	14.75%

In the previous week, DexCom had 15 more articles in the media than Penumbra. MarketBeat recorded 23 mentions for DexCom and 8 mentions for Penumbra. DexCom's average media sentiment score of 1.65 beat Penumbra's score of 1.51 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DexCom	22 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Penumbra has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, DexCom has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Penumbra currently has a consensus price target of $367.07, indicating a potential upside of 12.90%. DexCom has a consensus price target of $88.71, indicating a potential downside of 3.93%. Given Penumbra's higher possible upside, research analysts plainly believe Penumbra is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

DexCom beats Penumbra on 12 of the 17 factors compared between the two stocks.

Get Penumbra News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEN vs. The Competition

Export

Metric	Penumbra	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$12.81B	$6.02B	$7.37B	$24.30B
Dividend Yield	N/A	1.75%	2.53%	3.70%
P/E Ratio	79.89	26.67	272.60	30.31
Price / Sales	9.12	45.38	618.96	19.89
Price / Cash	75.64	33.24	78.62	32.49
Price / Book	8.37	6.23	13.05	6.77
Net Income	$177.69M	$150.07M	$3.47B	$1.07B
7 Day Performance	-0.54%	0.69%	2.09%	-0.65%
1 Month Performance	2.30%	8.91%	6.64%	3.38%
1 Year Performance	22.85%	8.07%	25.02%	14.90%

Penumbra Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEN Penumbra	3.7202 of 5 stars	$325.14 +0.4%	$367.07 +12.9%	+22.8%	$12.81B	$1.40B	79.89	4,700	Positive News
LNTH Lantheus	3.5626 of 5 stars	$100.91 0.0%	$108.11 +7.1%	+71.7%	$6.59B	$1.54B	24.37	1,193	Positive News
ITGR Integer	2.6564 of 5 stars	$125.13 -0.1%	$109.86 -12.2%	+13.2%	$4.26B	$1.85B	34.19	11,000
BDX Becton, Dickinson and Company	3.5774 of 5 stars	$182.39 -0.6%	$185.67 +1.8%	-3.8%	$50.53B	$21.84B	54.94	72,000	Positive News
IDXX IDEXX Laboratories	4.6245 of 5 stars	$546.09 -0.9%	$747.00 +36.8%	-13.7%	$43.41B	$4.30B	38.40	11,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PEN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Penumbra (PEN) Competitors